Breaking News Instant updates and real-time market news.

PFE

Pfizer

$33.56

-0.09 (-0.27%)

, MRK

Merck

$62.77

0.11 (0.18%)

18:10
10/09/16
10/09
18:10
10/09/16
18:10

Pfizer reports data on Inlyta-Keytruda, Inlyta-avelumab studies

Pfizer (PFE) announced data from an ongoing, investigational Phase 1b study of INLYTA combined with the checkpoint inhibitor pembrolizumab, a PD-1 inhibitor known as KEYTRUDA and marketed by Merck (MRK), in treatment-naive patients with advanced renal cell carcinoma. Preliminary results from a similar, separate study combining INLYTA with avelumab, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody that is being co-developed by Merck KGaA (MKGAY) and Pfizer were also presented. The data suggest evidence of anti-tumor activity for INLYTA in combination with avelumab. Based on these Phase 1 results, two independent global Phase 3 trials evaluating these combinations - INLYTA plus pembrolizumab and INLYTA plus avelumab - each compared with SUTENT in first-line advanced RCC are now enrolling patients. Specifically, early indicators from the A4061079 study point to strong response rates with the INLYTA/pembrolizumab combination, with 37 patients achieving objective responses, including three complete responses and 34 partial responses. 10 patients had stable disease and 5 patients had disease progression. Separately, in the JAVELIN Renal 100 study of INLYTA in combination with avelumab, five out of six patients treated so far had confirmed partial responses -- objective response rate 83.3% -- and one patient with tumor shrinkage not meeting partial response criteria had stable disease.

PFE

Pfizer

$33.56

-0.09 (-0.27%)

MRK

Merck

$62.77

0.11 (0.18%)

MKGAY

Merck KGaA

$35.88

0.1 (0.28%)

  • 25

    Oct

  • 01

    Nov

  • 06

    Nov

PFE Pfizer
$33.56

-0.09 (-0.27%)

08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
MKGAY Merck KGaA
$35.88

0.1 (0.28%)

08/12/16
BREN
08/12/16
DOWNGRADE
BREN
Hold
Merck KGaA downgraded to Hold from Buy at Berenberg

TODAY'S FREE FLY STORIES

CIVB

Civista

$22.15

0.04 (0.18%)

21:13
02/21/17
02/21
21:13
02/21/17
21:13
Syndicate
Civista 1.4M share Secondary priced at $21.75 »

Keefe Bruyette and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$76.24

-0.95 (-1.23%)

, SO

Southern Company

$48.28

0.48 (1.00%)

20:25
02/21/17
02/21
20:25
02/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$76.24

-0.95 (-1.23%)

SO

Southern Company

$48.28

0.48 (1.00%)

DISH

DISH

$62.82

-0.07 (-0.11%)

HST

Host Hotels

$18.69

0.3 (1.63%)

NCLH

Norwegian Cruise Line

$48.20

0.51 (1.07%)

MBLY

Mobileye

$46.12

0.47 (1.03%)

GRMN

Garmin

$50.45

-0.36 (-0.71%)

TOL

Toll Brothers

$31.99

0.5 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

MNTA

Momenta

20:19
02/21/17
02/21
20:19
02/21/17
20:19
Downgrade
Momenta rating change  »

Momenta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

MNTA

Momenta

$16.05

-2.95 (-15.53%)

20:19
02/21/17
02/21
20:19
02/21/17
20:19
Downgrade
Momenta rating change  »

Momenta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SNAP

Snap Inc

20:00
02/21/17
02/21
20:00
02/21/17
20:00
Periodicals
Goldman Sachs: Snap revenue could hit $2B in 2018, Business Insider reports »

Goldman Sachs, one of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

BA

Boeing

$175.56

2.85 (1.65%)

19:55
02/21/17
02/21
19:55
02/21/17
19:55
Periodicals
Boeing attempts to accelerate satellite manufacturing process, WSJ says »

Boeing is working to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DBOEY

Deutsche Boerse

$8.64

0.065 (0.76%)

19:50
02/21/17
02/21
19:50
02/21/17
19:50
Periodicals
Deutsche Boerse, LSE set to offer additional merger concessions, FT says »

Deutsche Boerse and LSE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$133.72

0.19 (0.14%)

19:35
02/21/17
02/21
19:35
02/21/17
19:35
Periodicals
Facebook nears deal to expand European headquarters, Bloomberg says »

Facebook is nearing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

GOOG

Alphabet

$831.66

3.59 (0.43%)

, GOOGL

Alphabet Class A

$849.27

2.72 (0.32%)

19:25
02/21/17
02/21
19:25
02/21/17
19:25
Periodicals
Google to discontinue 'Google Site Search,' Fortune says »

Google plans to…

GOOG

Alphabet

$831.66

3.59 (0.43%)

GOOGL

Alphabet Class A

$849.27

2.72 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 06

    Mar

  • 19

    Mar

WMT

Wal-Mart

$71.45

2.08 (3.00%)

19:20
02/21/17
02/21
19:20
02/21/17
19:20
Periodicals
Wal-Mart adds some in-house brands to Jet.com, Bloomberg says »

Wal-Mart subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

AAPL

Apple

$136.70

0.98 (0.72%)

19:13
02/21/17
02/21
19:13
02/21/17
19:13
Hot Stocks
Analytics firm: Average U.S. iPhone user spent $40 on apps in 2016 »

Analytics firm Sensor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

AMZN

Amazon.com

$856.44

11.37 (1.35%)

19:05
02/21/17
02/21
19:05
02/21/17
19:05
Periodicals
Amazon to sell beer, wine in 'Amazon Go' store, Recode says »

Amazon plans to sell beer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 14

    Mar

  • 19

    Mar

  • 28

    Mar

ARII

American Railcar

$46.03

-0.62 (-1.33%)

, IEP

Icahn Enterprises

$54.95

-1.03 (-1.84%)

19:01
02/21/17
02/21
19:01
02/21/17
19:01
Hot Stocks
American Railcar enters Consulting Services pact with American Railcar Leasing »

According to a regulatory…

ARII

American Railcar

$46.03

-0.62 (-1.33%)

IEP

Icahn Enterprises

$54.95

-1.03 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

FB

Facebook

$133.72

0.19 (0.14%)

, TWTR

Twitter

$16.42

-0.2 (-1.20%)

18:57
02/21/17
02/21
18:57
02/21/17
18:57
Periodicals
MLB in talks with Facebook to stream one game per week, Reuters says »

Facebook (FB) is in…

FB

Facebook

$133.72

0.19 (0.14%)

TWTR

Twitter

$16.42

-0.2 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

TX

Ternium

$23.69

0.13 (0.55%)

, TYEKF

ThyssenKrupp

18:50
02/21/17
02/21
18:50
02/21/17
18:50
Hot Stocks
Ternium to acquire CSA Siderurgica from ThyssenKrupp »

Ternium (TX) announced a…

TX

Ternium

$23.69

0.13 (0.55%)

TYEKF

ThyssenKrupp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTB

Butterfield

$32.93

-0.08 (-0.24%)

, CG

Carlyle Group

$16.20

0.15 (0.93%)

18:30
02/21/17
02/21
18:30
02/21/17
18:30
Syndicate
Butterfield announces offering of 9.56M shares of common stock for holders »

The Bank of N.T.…

NTB

Butterfield

$32.93

-0.08 (-0.24%)

CG

Carlyle Group

$16.20

0.15 (0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

CPRT

Copart

$60.30

1.29 (2.19%)

18:09
02/21/17
02/21
18:09
02/21/17
18:09
Earnings
Copart reports Q2 adjusted EPS 58c, consensus 57c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DAL

Delta Air Lines

$51.21

-0.02 (-0.04%)

18:07
02/21/17
02/21
18:07
02/21/17
18:07
Hot Stocks
Aeromexico says concludes Delta tender offer 'represents fair value' »

Grupo Aeromexico issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSS

Golden Star Resources

$0.99

0.0232 (2.40%)

18:04
02/21/17
02/21
18:04
02/21/17
18:04
Hot Stocks
Golden Star Resources sees FY17 gold production 255,000-280,000 »

Sees FY17 AISC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

GSS

Golden Star Resources

$0.99

0.0232 (2.40%)

17:57
02/21/17
02/21
17:57
02/21/17
17:57
Earnings
Golden Star Resources reports Q4 adjusted EPS 1c, consensus (1c) »

Reports Q4 gold revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CY

Cypress Semiconductor

$13.12

0.22 (1.71%)

17:52
02/21/17
02/21
17:52
02/21/17
17:52
Hot Stocks
Cypress Semiconductor founder nominates two candidates for board »

T.J. Rodgers, founder and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 16

    Mar

XPO

XPO Logistics

$48.38

-0.84 (-1.71%)

, DEPO

Depomed

$15.77

-0.7 (-4.25%)

17:41
02/21/17
02/21
17:41
02/21/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: XPO…

XPO

XPO Logistics

$48.38

-0.84 (-1.71%)

DEPO

Depomed

$15.77

-0.7 (-4.25%)

WMGI

Wright Medical

$26.86

-0.1 (-0.37%)

HCLP

Hi-Crush Partners

$21.40

0.1 (0.47%)

RRGB

Red Robin

$47.50

-0.3 (-0.63%)

FSLR

First Solar

$36.62

1.78 (5.11%)

LNTH

Lantheus

$9.35

-0.1 (-1.06%)

GE

General Electric

$30.52

0.15 (0.49%)

TRCO

Tribune Media

$33.70

0.73 (2.21%)

SREV

ServiceSource

$6.05

0.22 (3.77%)

FUEL

Rocket Fuel

$2.55

0.08 (3.24%)

TXRH

Texas Roadhouse

$47.79

-0.45 (-0.93%)

WLL

Whiting Petroleum

$11.57

0.46 (4.14%)

TEX

Terex

$32.13

0.13 (0.41%)

PZZA

Papa John's

$85.63

-0.38 (-0.44%)

FE

FirstEnergy

$31.33

0.32 (1.03%)

PKD

Parker Drilling

GBT

Global Blood Therapeutics

$28.50

1.6 (5.95%)

CUZ

Cousins Properties

$8.66

0.01 (0.12%)

YUM

Yum! Brands

$67.67

-0.73 (-1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 01

    Mar

  • 07

    Mar

  • 07

    Mar

  • 14

    Mar

  • 26

    Apr

  • 09

    May

  • 22

    Feb

GLA

GlassBridge

, IMN

Imation

$0.77

-0.0091 (-1.17%)

17:41
02/21/17
02/21
17:41
02/21/17
17:41
Hot Stocks
GlassBridge implements name change, reverse stock split »

GlassBridge Enterprises…

GLA

GlassBridge

IMN

Imation

$0.77

-0.0091 (-1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HVT

Haverty Furniture

$22.95

0.4 (1.77%)

17:37
02/21/17
02/21
17:37
02/21/17
17:37
Earnings
Haverty Furniture reports Q4 EPS 51c, consensus 43c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CUZ

Cousins Properties

$8.66

0.01 (0.12%)

17:36
02/21/17
02/21
17:36
02/21/17
17:36
Syndicate
Breaking Syndicate news story on Cousins Properties »

Cousins announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.